Next Article in Journal
Towards Clinical Translation of CD8+ Regulatory T Cells Restricted by Non-Classical Major Histocompatibility Complex Ib Molecules
Next Article in Special Issue
Multiplexed Competitive Screening of One-Bead-One-Component Combinatorial Libraries Using a ClonePix 2 Colony Sorter
Previous Article in Journal
Selecting an Appropriate Animal Model of Depression
Previous Article in Special Issue
Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats
Open AccessArticle

Novel Genetic Markers for Early Detection of Elevated Breast Cancer Risk in Women

1
Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA
2
Computational Biophysics and Bioinformatics, Department of Physics, Clemson University, Clemson, SC 29634, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(19), 4828; https://doi.org/10.3390/ijms20194828
Received: 2 September 2019 / Revised: 20 September 2019 / Accepted: 25 September 2019 / Published: 28 September 2019
(This article belongs to the Collection Feature Papers in Molecular Biophysics)
This study suggests that two newly discovered variants in the MSH2 gene, which codes for a DNA mismatch repair (MMR) protein, can be associated with a high risk of breast cancer. While variants in the MSH2 gene are known to be linked with an elevated cancer risk, the MSH2 gene is not a part of the standard kit for testing patients for elevated breast cancer risk. Here we used the results of genetic testing of women diagnosed with breast cancer, but who did not have variants in BRCA1 and BRCA2 genes. Instead, the test identified four variants with unknown significance (VUS) in the MSH2 gene. Here, we carried in silico analysis to develop a classifier that can distinguish pathogenic from benign mutations in MSH2 genes taken from ClinVar. The classifier was then used to classify VUS in MSH2 genes, and two of them, p.Ala272Val and p.Met592Val, were predicted to be pathogenic mutations. These two mutations were found in women with breast cancer who did not have mutations in BRCA1 and BRCA2 genes, and thus they are suggested to be considered as new bio-markers for the early detection of elevated breast cancer risk. However, before this is done, an in vitro validation of mutation pathogenicity is needed and, moreover, the presence of these mutations should be demonstrated in a higher number of patients or in families with breast cancer history. View Full-Text
Keywords: MSH2; breast cancer; personalized medicine; early diagnostics; computational modeling; disease-causing mutations; variants MSH2; breast cancer; personalized medicine; early diagnostics; computational modeling; disease-causing mutations; variants
Show Figures

Graphical abstract

MDPI and ACS Style

Wu, B.; Peng, Y.; Eggert, J.; Alexov, E. Novel Genetic Markers for Early Detection of Elevated Breast Cancer Risk in Women. Int. J. Mol. Sci. 2019, 20, 4828.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop